Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Endocrinology and Metabolism Clinics of North America|January 25, 2024
Emerging Technologies and Therapeutics for Type 1 DiabetesHalis Kaan Akturk, Alexis M McKee
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|May 15, 2021
Disparities in Utilization and Outcomes With Continuous Subcutaneous Insulin Infusion in Young Adults With Type 1 DiabetesAlexis M McKee, Noor Al-Hammadi, Leslie J Hinyard
Endocrinology, Diabetes & Metabolism|July 19, 2021
Outcomes for continuous subcutaneous insulin infusion users in young adults from lower socioeconomic backgroundsAlexis M McKee, Stewart G Albert, Noor Al-Hammadi, et al.
Clinical Diabetes : a Publication of the American Diabetes Association|July 17, 2023
The Nuances Surrounding Insulin PrescribingAlexis M McKee, Abigail M Yancey, Rong M Zhang, et al.
Journal of Diabetes Science and Technology|February 24, 2023
Interruption of Continuous Glucose Monitoring: Frequency and Adverse ConsequencesAlexander M Markov, Petra Krutilova, Andrea E Cedeno, et al.
Anesthesia and Analgesia|June 24, 2024
Perioperative Care of Patients Using Wearable Diabetes DevicesPaulina Cruz, Alexis M McKee, Hou-Hsien Chiang, et al.
Medrxiv : the Preprint Server for Health Sciences|February 20, 2025
Breath Acetone Correlates with Capillary β-hydroxybutyrate in Type 1 DiabetesKai E Jones, Max C Petersen, Alexander M Markov, et al.
Journal of Diabetes Science and Technology|April 22, 2025
Breath Acetone Correlates With Capillary β-hydroxybutyrate in Type 1 DiabetesKai E Jones, Max C Petersen, Alexander M Markov, et al.
Diabetes, Obesity & Metabolism|March 14, 2025
Effect of dapagliflozin on blood and breath ketones during supervised insulin withdrawal in adults with type 1 diabetes: A randomized crossover trialMax C Petersen, Kai E Jones, Alexander M Markov, et al.
Cancer & Metabolism|May 18, 2023
Safety, tolerability, and effectiveness of the sodium-glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin in combination with standard chemotherapy for patients with advanced, inoperable pancreatic adenocarcinoma: a phase 1b observational studyLauren K Park, Kian-Huat Lim, Jonas Volkman, et al.
Pageof 1